48,830
edits
(→Pancreas neoplasms in a table: wikify) |
|||
Line 787: | Line 787: | ||
*[http://path.upmc.edu/cases/case339.html Pancreatic NET with features of SPT (upmc.edu)]. | *[http://path.upmc.edu/cases/case339.html Pancreatic NET with features of SPT (upmc.edu)]. | ||
*[http://path.upmc.edu/cases/case501.html Pancreatic NET - another case (upmc.edu)]. | *[http://path.upmc.edu/cases/case501.html Pancreatic NET - another case (upmc.edu)]. | ||
===IHC=== | |||
*CK19 +ve -- should be done as a routine in pancreatic NETs; poor prognostic factor.<ref name=pmid19956064>{{Cite journal | last1 = Jain | first1 = R. | last2 = Fischer | first2 = S. | last3 = Serra | first3 = S. | last4 = Chetty | first4 = R. | title = The use of Cytokeratin 19 (CK19) immunohistochemistry in lesions of the pancreas, gastrointestinal tract, and liver. | journal = Appl Immunohistochem Mol Morphol | volume = 18 | issue = 1 | pages = 9-15 | month = Jan | year = 2010 | doi = 10.1097/PAI.0b013e3181ad36ea | PMID = 19956064 }}</ref> | |||
==Acinar cell carcinoma of the pancreas== | ==Acinar cell carcinoma of the pancreas== |
edits